Overview

ALN-APOC3 in Adult Participants With Dyslipidemia

Status:
RECRUITING
Trial end date:
2027-07-05
Target enrollment:
Participant gender:
Summary
This study is researching an experimental drug called ALN-APOC3 (called "study drug"). The study is focused on participants who have dyslipidemia (abnormal amounts of fats in the blood, including triglycerides and cholesterol), but who are otherwise healthy. The aim of the study is to see how safe and effective the study drug is. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * How the study drug changes lipid levels in the blood
Phase:
PHASE1
Details
Lead Sponsor:
Regeneron Pharmaceuticals